Experts Propose New Consensus Scale for CAR T-cell Therapy Toxicities

The American Society for Blood and Bone Marrow Transplantation published a consensus grading tool for cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS), two adverse events seen with CAR T-cell therapy. Their proposal includes a grade 1-5 scale for CRS, ranging from fever to death, and two separate scales for ICANS focused on adult and pediatric patients, respectively.

Lymphoma News Daily